U.S. Markets open in 4 hrs 20 mins

Teva Pharmaceutical Industries Limited (TEVA)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
32.64+0.21 (+0.65%)
At close: 4:02PM EDT
People also watch
MYLGILDNVSAMGNBMY
Full screen
Previous Close32.43
Open32.40
Bid32.23 x 1000
Ask32.37 x 200
Day's Range32.23 - 32.65
52 Week Range27.60 - 55.79
Volume3,251,371
Avg. Volume8,073,422
Market Cap33.14B
Beta0.49
PE Ratio (TTM)418.46
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.36 (4.17%)
Ex-Dividend Date2017-06-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters23 hours ago

    Teva Pharm to reduce workforce in Israel, mainly in production

    Teva Pharmaceutical Industries said on Sunday it would lay off some of its 7,000 employees in Israel in the coming months as it reorganises in a drive to improve competitiveness. Teva, Israel's largest company, did not specify how many workers would leave, but a source close to the process told Reuters the number would be about 350, mainly in production. "In light of the complex business reality the entire pharmaceutical industry and Teva in particular face, Teva has been implementing in recent years a global reorganisation," it said in a statement.

  • TheStreet.com3 days ago

    7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods

    Here are the activist investor's next potential targets.

  • Reuters3 days ago

    AstraZeneca CEO reassures staff, aims to be at September cancer meet

    AstraZeneca Chief Executive Pascal Soriot, responding to rumors he might leave the drugmaker to join rival Teva Pharmaceutical Industries, has told staff he expects to work "together" with employees to see the company succeed. A company spokeswoman added he was intending to attend the European Society for Medical Oncology annual meeting in Madrid in September, assuming that AstraZeneca had clinical data on its new immunotherapy medicine ready to present at the event. Soriot did not comment on whether he had received a job offer from Teva in the internal memo to staff, which was sent out at the start of this week.